title: Should we measure quality by the dose?
authors: Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Clinical Research Institute, Boston, Massachusetts. Electronic address: cpcannon@partners.org.
authors: Christopher P
authors: CP
authors: Cannon
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage*; D047228:Angiotensin II Type 1 Receptor Blockers / Q000008:administration & dosage*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage*; D008297:Male; D009203:Myocardial Infarction / Q000188:drug therapy*; D055502:Secondary Prevention / Q000379:methods*
chemical_list: D000319:Adrenergic beta-Antagonists; D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors
keywords: guidelines; myocardial infarction; performance measures; quality improvement; secondary prevention